These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3872057)

  • 41. Enhanced bioavailability of verapamil after oral administration with hesperidin in rats.
    Piao YJ; Choi JS
    Arch Pharm Res; 2008 Apr; 31(4):518-22. PubMed ID: 18449511
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Electrophysiological effects of bepridil and its quaternary derivative CERM 11888 in closed chest anaesthetized dogs: a comparison with verapamil and diltiazem.
    Leboeuf J; Lamar JC; Massingham R; Ponsonnaille J
    Br J Pharmacol; 1989 Dec; 98(4):1351-9. PubMed ID: 2611495
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers.
    Böttiger Y; Säwe J; Brattström C; Tollemar J; Burke JT; Häss G; Zimmerman JJ
    Clin Pharmacol Ther; 2001 Jan; 69(1):32-40. PubMed ID: 11180036
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ca2+ uptake and energy supply of sheep heart mitochondria in presence of some calcium antagonists.
    Leblondel G; Allain P
    Res Commun Chem Pathol Pharmacol; 1984 Jun; 44(3):499-502. PubMed ID: 6611569
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical pharmacokinetics of the newer antiarrhythmic agents.
    Gillis AM; Kates RE
    Clin Pharmacokinet; 1984; 9(5):375-403. PubMed ID: 6437721
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of the calcium antagonists bepridil (CERM-1978) and verapamil on Ca++-dependent slow action potentials in frog skeletal muscle.
    Kerr LM; Sperelakis N
    J Pharmacol Exp Ther; 1982 Jul; 222(1):80-6. PubMed ID: 6979625
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of bepridil hydrochloride on calcium-induced responses in guinea pig Langendorff heart.
    Gleason MM; Gill A; Brannan MD; Flaim SF
    Pharmacology; 1986; 33(2):76-85. PubMed ID: 3488555
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.
    Johnsson G; Regàrdh CG
    Clin Pharmacokinet; 1976; 1(4):233-63. PubMed ID: 13958
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression.
    Fleishaker JC
    Clin Pharmacokinet; 2000 Dec; 39(6):413-27. PubMed ID: 11192474
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Kinetics and dynamics of calcium entry antagonists in systemic hypertension.
    McAllister RG; Schloemer GL; Hamann SR
    Am J Cardiol; 1986 Feb; 57(7):16D-21D. PubMed ID: 3513512
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative study of bepridil and nicardipine action on respiration and calcium transport in mitochondria.
    Tari C; Fournier N; Ducet G; Crevat A; Albengres E; Urien S; Tillement JP
    Int J Clin Pharmacol Ther Toxicol; 1987 Jan; 25(1):26-30. PubMed ID: 2951341
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.
    Säwe J
    Clin Pharmacokinet; 1986; 11(2):87-106. PubMed ID: 3514045
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Different interaction of bepridil and diltiazem with BAY K 8644 in the abolition of autoregulation of renal blood flow.
    Ogawa N; Yokota S; Ono H
    J Cardiovasc Pharmacol; 1988 Feb; 11(2):147-50. PubMed ID: 2452307
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Drug interactions with calcium inhibitors in man].
    Cheymol G; Engel F
    Therapie; 1989; 44(3):189-96. PubMed ID: 2571195
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bepridil hydrochloride alters potential-dependent and receptor-operated calcium channels in vascular smooth muscle of rabbit aorta.
    Flaim SF; Ratz PH; Swigart SC; Gleason MM
    J Pharmacol Exp Ther; 1985 Jul; 234(1):63-71. PubMed ID: 2409274
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design.
    DeVane CL; Gill HS
    J Clin Psychiatry; 1997; 58 Suppl 5():7-14. PubMed ID: 9184622
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination propranolol and bepridil therapy in stable angina pectoris.
    Frishman WH; Charlap S; Farnham DJ; Sawin HS; Michelson EL; Crawford MH; DiBianco R; Kostis JB; Zellner SR; Michie DD
    Am J Cardiol; 1985 Mar; 55(7):43C-49C. PubMed ID: 3883741
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of the controlled-release nisoldipine coat-core tablet formulation.
    Heinig R; Ahr G; Hayauchi Y; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):341-51. PubMed ID: 9266290
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of sodium-calcium exchange in cardiac sarcolemmal membrane vesicles. 2. Mechanism of inhibition by bepridil.
    Garcia ML; Slaughter RS; King VF; Kaczorowski GJ
    Biochemistry; 1988 Apr; 27(7):2410-5. PubMed ID: 3260109
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative efficacy of 200, 300 and 400 mg of bepridil for chronic stable angina pectoris.
    Shapiro W; DiBianco R; Thadani U
    Am J Cardiol; 1985 Mar; 55(7):36C-42C. PubMed ID: 3919556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.